Alexandra C. Sundermann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alexandra C. Sundermann has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Katherine E. Hartmann
Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, USA
9 shared publications - Digna R. Velez Edwards
Division of Quantitative and Clinical Sciences, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, USA
5 shared publications Pingsheng Wu
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN
4 shared publicationsDigna R Velez Edwards
Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
3 shared publicationsDigna R. Velez Edwards
Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN
3 shared publicationsSarah H. Jones
Division of Quantitative and Clinical Sciences, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, USA
3 shared publications
Latest Publications
- Open Access
Indications for cesarean delivery among patients with life‐limiting fetal diagnoses
Introduction: Mode of delivery is uniquely complex when a neonate is not expected to survive after birth. Cesarean delivery (CD) generally confers increased maternal morbidity but may be pursued to mitigate intrapartum fetal risk. Prior studies have reported elevated CD rates among patients with a life‐limiting fetal diagnosis (LLFD) but have not characterized the indications that drive this increase. We sought to characterize the proportion and indications for CD among patients with selected LLFDs. Methods: This retrospective cohort includes patients with an antenatal LLFD who delivered at a tertiary care center between January 1, 2018 and May 1, 2025 at or above 24 weeks' gestation. LLFD cases were chosen for inclusion after manual review by Maternal‐Fetal Medicine and Neonatology subspecialists, and the cohort was further restricted to six LLFDs: anencephaly, trisomy 13, trisomy 18, anhydramnios due to genitourinary etiologies, limb‐body wall complex, and severe skeletal dysplasia. The primary outcome was CD; the secondary outcome was indication for CD. Results: Of 32,523 eligible deliveries, 241 were identified as having an antenatal LLFD; after restriction to six prespecified diagnoses, the final LLFD cohort included 106 patients. CD occurred in 42.5% of LLFD pregnancies. Proportion of deliveries by CD varied by diagnosis: 0% in anencephaly, 36.4% in skeletal dysplasia, 40.0% in trisomy 13, 45.8% in trisomy 18, 40.0% in limb/body wall complex, and 54.5% in anhydramnios due to a genitourinary cause. A total of 53.3% of CDs were performed for a fetal indication, most commonly malpresentation and non‐reassuring fetal status. Conclusion: Driven by fetal indications for delivery, patients with a known LLFD underwent CD in 42.5% of pregnancies, with substantial variation across diagnoses. It is unclear whether the increased proportion of CD is driven by traditional obstetric indications or patient‐centered choices regarding the delivery experience.
Open AccessIndications for cesarean delivery among patients with life‐limiting fetal diagnoses
Introduction: Mode of delivery is uniquely complex when a neonate is not expected to survive after birth. Cesarean delivery (CD) generally confers increased maternal morbidity but may be pursued to mitigate intrapartum fetal risk. Prior studies have reported elevated CD rates among patients with a life‐limiting fetal diagnosis (LLFD) but have not characterized the indications that drive this increase. We sought to characterize the proportion and indications for CD among patients with selected LLFDs. Methods: This retrospective cohort includes patients with an antenatal LLFD who delivered at a tertiary care center between January 1, 2018 and May 1, 2025 at or above 24 weeks' gestation. LLFD cases were chosen for inclusion after manual review by Maternal‐Fetal Medicine and Neonatology subspecialists, and the cohort was further restricted to six LLFDs: anencephaly, trisomy 13, trisomy 18, anhydramnios due to genitourinary etiologies, limb‐body wall complex, and severe skeletal dysplasia. The primary outcome was CD; the secondary outcome was indication for CD. Results: Of 32,523 eligible deliveries, 241 were identified as having an antenatal LLFD; after restriction to six prespecified diagnoses, the final LLFD cohort included 106 patients. CD occurred in 42.5% of LLFD pregnancies. Proportion of deliveries by CD varied by diagnosis: 0% in anencephaly, 36.4% in skeletal dysplasia, 40.0% in trisomy 13, 45.8% in trisomy 18, 40.0% in limb/body wall complex, and 54.5% in anhydramnios due to a genitourinary cause. A total of 53.3% of CDs were performed for a fetal indication, most commonly malpresentation and non‐reassuring fetal status. Conclusion: Driven by fetal indications for delivery, patients with a known LLFD underwent CD in 42.5% of pregnancies, with substantial variation across diagnoses. It is unclear whether the increased proportion of CD is driven by traditional obstetric indications or patient‐centered choices regarding the delivery experience.
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (3)
Patterns of Patient-Reported Awareness About Early-Onset Cancer-Related Infertility Risk
PURPOSE: Reproductive care—including discussions about cancer-related infertility risk—is part of the recommended standard of care for all patients with cancer. Despite rising cancer incidence among adults younger than 50 years (early-onset), the evaluation of patients' knowledge about cancer-related infertility risk is limited. We characterized factors associated with lack of awareness of potential cancer-related infertility risk as reported by patients with early-onset cancer. PATIENTS AND METHODS: Using data from the Reproductive Health After Cancer Diagnosis and Treatment (REACT) Study, we identified individuals diagnosed with a first primary early-onset cancer between 2006 and 2021. Awareness of potential cancer-related infertility risk was determined using questionnaires. Logistic regression models were fitted to examine associations between a lack of awareness of cancer-related infertility risk and patient-level factors. RESULTS: Among 636 patients, 28.9% (n = 184) reported never being told that their cancer treatments may affect their fertility. Patients who were aware of a potential cancer-related infertility risk had heard this information, on average, from two unique sources (mean = 2.2, std = 1.3)—with 90.1% of all sources derived from clinical interactions/settings. Patients who self-identified with a racial ethnic minority (REM) population—inclusive of African American/Black, American Indian, Asian, Hispanic/Spanish/Latino/a/x, Middle Eastern or North African, or multiple races—were nearly twice as likely to report an unawareness of infertility risk compared with patients who identified as non-Hispanic White after adjusting for diagnosis age and year, sex, insurance coverage, marital status, and pregnancy history (odds ratio, 1.70 [95% CI, 1.05 to 2.74]; P = .03). CONCLUSION: Three in every 10 patients with early-onset cancer reported never having been told that cancer treatments may affect their fertility. Individual factors contributed to differences in patients' knowledge of potential cancer-related infertility risk. Further study is needed to address this care gap among patients and providers to deliver concordant, high-quality reproductive and oncology care to this growing population.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (3)
Open AccessPatterns of Patient-Reported Awareness About Early-Onset Cancer-Related Infertility Risk
PURPOSE: Reproductive care—including discussions about cancer-related infertility risk—is part of the recommended standard of care for all patients with cancer. Despite rising cancer incidence among adults younger than 50 years (early-onset), the evaluation of patients' knowledge about cancer-related infertility risk is limited. We characterized factors associated with lack of awareness of potential cancer-related infertility risk as reported by patients with early-onset cancer. PATIENTS AND METHODS: Using data from the Reproductive Health After Cancer Diagnosis and Treatment (REACT) Study, we identified individuals diagnosed with a first primary early-onset cancer between 2006 and 2021. Awareness of potential cancer-related infertility risk was determined using questionnaires. Logistic regression models were fitted to examine associations between a lack of awareness of cancer-related infertility risk and patient-level factors. RESULTS: Among 636 patients, 28.9% (n = 184) reported never being told that their cancer treatments may affect their fertility. Patients who were aware of a potential cancer-related infertility risk had heard this information, on average, from two unique sources (mean = 2.2, std = 1.3)—with 90.1% of all sources derived from clinical interactions/settings. Patients who self-identified with a racial ethnic minority (REM) population—inclusive of African American/Black, American Indian, Asian, Hispanic/Spanish/Latino/a/x, Middle Eastern or North African, or multiple races—were nearly twice as likely to report an unawareness of infertility risk compared with patients who identified as non-Hispanic White after adjusting for diagnosis age and year, sex, insurance coverage, marital status, and pregnancy history (odds ratio, 1.70 [95% CI, 1.05 to 2.74]; P = .03). CONCLUSION: Three in every 10 patients with early-onset cancer reported never having been told that cancer treatments may affect their fertility. Individual factors contributed to differences in patients' knowledge of potential cancer-related infertility risk. Further study is needed to address this care gap among patients and providers to deliver concordant, high-quality reproductive and oncology care to this growing population.
- Open Access
- 16 June 2026
- Published by Elsevier in Fertility and Sterility
- Vol. 126 (4) , 693-700
Home pregnancy test sensitivity by test timing and cycle length with real-world use among pregnancy planners who conceived
- 16 June 2026
- Published by Elsevier in Fertility and Sterility
- Vol. 126 (4) , 693-700
Open AccessHome pregnancy test sensitivity by test timing and cycle length with real-world use among pregnancy planners who conceived
- Open Access
- 23 April 2026
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 26 (3) , 16
A randomized trial to evaluate attitudes regarding pharmacogenomics among pregnant and pediatric populations: design and baseline characteristics
Pharmacogenomics (PGx) is a key component of precision medicine, yet most PGx studies exclude pregnant people and children. The VICE (Vanderbilt Integrated Center of Excellence)-MPRINT (Maternal and Pediatric Precision in Therapeutics): Maternal and Pediatric Pharmacogenetics Trial is a single-center, randomized control trial to assess how PGx testing and return of results influence patients’ understanding and perceived utility of PGx testing in a pregnancy and pediatric cohort. Pregnant individuals and families or guardians of children with a chronic health condition aged 0–16 were recruited. We assessed participants’ knowledge and attitudes regarding PGx testing at baseline and after receiving results with patient-friendly interpretations. Cases received an educational video about PGx testing with return of results. Controls received PGx test results alone. We aimed to determine perspectives regarding PGx in these understudied populations with the goal of promoting research and clinical implementation of PGx for pregnant women and children.
- 23 April 2026
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 26 (3) , 16
Open AccessA randomized trial to evaluate attitudes regarding pharmacogenomics among pregnant and pediatric populations: design and baseline characteristics
Pharmacogenomics (PGx) is a key component of precision medicine, yet most PGx studies exclude pregnant people and children. The VICE (Vanderbilt Integrated Center of Excellence)-MPRINT (Maternal and Pediatric Precision in Therapeutics): Maternal and Pediatric Pharmacogenetics Trial is a single-center, randomized control trial to assess how PGx testing and return of results influence patients’ understanding and perceived utility of PGx testing in a pregnancy and pediatric cohort. Pregnant individuals and families or guardians of children with a chronic health condition aged 0–16 were recruited. We assessed participants’ knowledge and attitudes regarding PGx testing at baseline and after receiving results with patient-friendly interpretations. Cases received an educational video about PGx testing with return of results. Controls received PGx test results alone. We aimed to determine perspectives regarding PGx in these understudied populations with the goal of promoting research and clinical implementation of PGx for pregnant women and children.
- 7 June 2023
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 229 (3) , 324.e1-324.e7
Maternal morbidity and mortality among patients with cancer at time of delivery
- 7 June 2023
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 229 (3) , 324.e1-324.e7
Maternal morbidity and mortality among patients with cancer at time of delivery
- 19 May 2022
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 227 (5) , 786-788.e2
Maternal alcohol metabolism predicted by alcohol dehydrogenase genotype and the association between alcohol consumption and miscarriage
- 19 May 2022
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 227 (5) , 786-788.e2
Maternal alcohol metabolism predicted by alcohol dehydrogenase genotype and the association between alcohol consumption and miscarriage
- 13 July 2020
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 224 (1) , 97.e1-97.e16
Week-by-week alcohol consumption in early pregnancy and spontaneous abortion risk: a prospective cohort study
- 13 July 2020
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 224 (1) , 97.e1-97.e16
Week-by-week alcohol consumption in early pregnancy and spontaneous abortion risk: a prospective cohort study
- 13 June 2019
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 43 (8) , 1606-1616
Alcohol Use in Pregnancy and Miscarriage: A Systematic Review and Meta‐Analysis
To systematically review and critically evaluate studies reporting alcohol exposure during pregnancy and miscarriage. We searched PubMed, EMBASE, PsycINFO, and ProQuest Theses for publications from January 1970 to January 2019. We identified studies about alcohol exposure during pregnancy and miscarriage. Information about study population, alcohol exposure assessment, outcome definition, covariates, and measures of association was collected. We assessed study quality using an adapted Newcastle‐Ottawa Scale. Data were abstracted by 2 investigators independently. We conducted a random‐effects meta‐analysis to calculate the association between alcohol exposure and miscarriage risk and performed subgroup analyses to determine robustness of results to study differences. For studies reporting dose‐specific effects, a pooled dose–response association was estimated using generalized least squares regression with and without restricted cubic spline terms for number of drinks consumed per week. Of 2,164 articles identified, 24 were eligible for inclusion. Meta‐analysis of data from 231,808 pregnant women finds those exposed to alcohol during pregnancy have a greater risk of miscarriage compared to those who abstained (odds ratio [OR] 1.19, 95% confidence intervals [CI] 1.12, 1.28). Estimates did not vary by study design, study country, or method of alcohol ascertainment. For alcohol use of 5 or fewer drinks per week, each additional drink per week was associated with a 6% increase in miscarriage risk (OR 1.06, 95% CI 1.01, 1.10). Common study limitations reflect challenges inherent to this research, including difficulty recruiting participants early enough in pregnancy to observe miscarriage and collecting and quantifying information about alcohol consumption during pregnancy that accurately reflects use. This review provides evidence that alcohol consumption during pregnancy is associated with a dose‐mediated increase in miscarriage risk. Future studies evaluating change in alcohol use in pregnancy are needed to provide insight into how alcohol consumption prior to pregnancy recognition impacts risk.
- 13 June 2019
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 43 (8) , 1606-1616
Alcohol Use in Pregnancy and Miscarriage: A Systematic Review and Meta‐Analysis
To systematically review and critically evaluate studies reporting alcohol exposure during pregnancy and miscarriage. We searched PubMed, EMBASE, PsycINFO, and ProQuest Theses for publications from January 1970 to January 2019. We identified studies about alcohol exposure during pregnancy and miscarriage. Information about study population, alcohol exposure assessment, outcome definition, covariates, and measures of association was collected. We assessed study quality using an adapted Newcastle‐Ottawa Scale. Data were abstracted by 2 investigators independently. We conducted a random‐effects meta‐analysis to calculate the association between alcohol exposure and miscarriage risk and performed subgroup analyses to determine robustness of results to study differences. For studies reporting dose‐specific effects, a pooled dose–response association was estimated using generalized least squares regression with and without restricted cubic spline terms for number of drinks consumed per week. Of 2,164 articles identified, 24 were eligible for inclusion. Meta‐analysis of data from 231,808 pregnant women finds those exposed to alcohol during pregnancy have a greater risk of miscarriage compared to those who abstained (odds ratio [OR] 1.19, 95% confidence intervals [CI] 1.12, 1.28). Estimates did not vary by study design, study country, or method of alcohol ascertainment. For alcohol use of 5 or fewer drinks per week, each additional drink per week was associated with a 6% increase in miscarriage risk (OR 1.06, 95% CI 1.01, 1.10). Common study limitations reflect challenges inherent to this research, including difficulty recruiting participants early enough in pregnancy to observe miscarriage and collecting and quantifying information about alcohol consumption during pregnancy that accurately reflects use. This review provides evidence that alcohol consumption during pregnancy is associated with a dose‐mediated increase in miscarriage risk. Future studies evaluating change in alcohol use in pregnancy are needed to provide insight into how alcohol consumption prior to pregnancy recognition impacts risk.
- Open Access
- 28 August 2018
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 15 (8) , e1002642
Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records
Observations from statin clinical trials and from Mendelian randomization studies suggest that low low-density lipoprotein cholesterol (LDL-C) concentrations may be associated with increased risk of type 2 diabetes mellitus (T2DM). Despite the findings from statin clinical trials and genetic studies, there is little direct evidence implicating low LDL-C concentrations in increased risk of T2DM. We used de-identified electronic health records (EHRs) at Vanderbilt University Medical Center to compare the risk of T2DM in a cross-sectional study among individuals with very low (≤60 mg/dl, N = 8,943) and normal (90–130 mg/dl, N = 71,343) LDL-C levels calculated using the Friedewald formula. LDL-C levels associated with statin use, hospitalization, or a serum albumin level < 3 g/dl were excluded. We used a 2-phase approach: in 1/3 of the sample (discovery) we used T2DM phenome-wide association study codes (phecodes) to identify cases and controls, and in the remaining 2/3 (validation) we identified T2DM cases and controls using a validated algorithm. The analysis plan for the validation phase was constructed at the time of the design of that component of the study. The prevalence of T2DM in the very low and normal LDL-C groups was compared using logistic regression with adjustment for age, race, sex, body mass index (BMI), high-density lipoprotein cholesterol, triglycerides, and duration of care. Secondary analyses included prespecified stratification by sex, race, BMI, and LDL-C level. In the discovery cohort, phecodes related to T2DM were significantly more frequent in the very low LDL-C group. In the validation cohort (N = 33,039 after applying the T2DM algorithm to identify cases and controls), the risk of T2DM was increased in the very low compared to normal LDL-C group (odds ratio [OR] 2.06, 95% CI 1.80–2.37; P < 2 × 10−16). The findings remained significant in sensitivity analyses. The association between low LDL-C levels and T2DM was significant in males (OR 2.43, 95% CI 2.00–2.95; P < 2 × 10−16) and females (OR 1.74, 95% CI 1.42–2.12; P = 6.88 × 10−8); in normal weight (OR 2.18, 95% CI 1.59–2.98; P = 1.1× 10−6), overweight (OR 2.17, 95% CI 1.65–2.83; P = 1.73× 10−8), and obese (OR 2.00, 95% CI 1.65–2.41; P = 8 × 10−13) categories; and in individuals with LDL-C < 40 mg/dl (OR 2.31, 95% CI 1.71–3.10; P = 3.01× 10−8) and LDL-C 40–60 mg/dl (OR 1.99, 95% CI 1.71–2.32; P < 2.0× 10−16). The association was significant in individuals of European ancestry (OR 2.67, 95% CI 2.25–3.17; P < 2 × 10−16) but not in those of African ancestry (OR 1.09, 95% CI 0.81–1.46; P = 0.56). A limitation was that we only compared groups with very low and normal LDL-C levels; also, since this was not an inception cohort, we cannot exclude the possibility of reverse causation. Very low LDL-C concentrations occurring in the absence of statin treatment were significantly associated with T2DM risk in a large EHR population; this increased risk was present in both sexes and all BMI categories, and in individuals of European ancestry but not of African ancestry. Longitudinal cohort studies to assess the relationship between very low LDL-C levels not associated with lipid-lowering therapy and risk of developing T2DM will be important.
- 28 August 2018
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 15 (8) , e1002642
Open AccessRelationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records
Observations from statin clinical trials and from Mendelian randomization studies suggest that low low-density lipoprotein cholesterol (LDL-C) concentrations may be associated with increased risk of type 2 diabetes mellitus (T2DM). Despite the findings from statin clinical trials and genetic studies, there is little direct evidence implicating low LDL-C concentrations in increased risk of T2DM. We used de-identified electronic health records (EHRs) at Vanderbilt University Medical Center to compare the risk of T2DM in a cross-sectional study among individuals with very low (≤60 mg/dl, N = 8,943) and normal (90–130 mg/dl, N = 71,343) LDL-C levels calculated using the Friedewald formula. LDL-C levels associated with statin use, hospitalization, or a serum albumin level < 3 g/dl were excluded. We used a 2-phase approach: in 1/3 of the sample (discovery) we used T2DM phenome-wide association study codes (phecodes) to identify cases and controls, and in the remaining 2/3 (validation) we identified T2DM cases and controls using a validated algorithm. The analysis plan for the validation phase was constructed at the time of the design of that component of the study. The prevalence of T2DM in the very low and normal LDL-C groups was compared using logistic regression with adjustment for age, race, sex, body mass index (BMI), high-density lipoprotein cholesterol, triglycerides, and duration of care. Secondary analyses included prespecified stratification by sex, race, BMI, and LDL-C level. In the discovery cohort, phecodes related to T2DM were significantly more frequent in the very low LDL-C group. In the validation cohort (N = 33,039 after applying the T2DM algorithm to identify cases and controls), the risk of T2DM was increased in the very low compared to normal LDL-C group (odds ratio [OR] 2.06, 95% CI 1.80–2.37; P < 2 × 10−16). The findings remained significant in sensitivity analyses. The association between low LDL-C levels and T2DM was significant in males (OR 2.43, 95% CI 2.00–2.95; P < 2 × 10−16) and females (OR 1.74, 95% CI 1.42–2.12; P = 6.88 × 10−8); in normal weight (OR 2.18, 95% CI 1.59–2.98; P = 1.1× 10−6), overweight (OR 2.17, 95% CI 1.65–2.83; P = 1.73× 10−8), and obese (OR 2.00, 95% CI 1.65–2.41; P = 8 × 10−13) categories; and in individuals with LDL-C < 40 mg/dl (OR 2.31, 95% CI 1.71–3.10; P = 3.01× 10−8) and LDL-C 40–60 mg/dl (OR 1.99, 95% CI 1.71–2.32; P < 2.0× 10−16). The association was significant in individuals of European ancestry (OR 2.67, 95% CI 2.25–3.17; P < 2 × 10−16) but not in those of African ancestry (OR 1.09, 95% CI 0.81–1.46; P = 0.56). A limitation was that we only compared groups with very low and normal LDL-C levels; also, since this was not an inception cohort, we cannot exclude the possibility of reverse causation. Very low LDL-C concentrations occurring in the absence of statin treatment were significantly associated with T2DM risk in a large EHR population; this increased risk was present in both sexes and all BMI categories, and in individuals of European ancestry but not of African ancestry. Longitudinal cohort studies to assess the relationship between very low LDL-C levels not associated with lipid-lowering therapy and risk of developing T2DM will be important.
- 9 July 2018
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 80 (4) , e13020
Gestational diabetes mellitus is associated with increased CD163 expression and iron storage in the placenta
Problem: GDM has been associated with disturbances in iron homeostasis and exaggerated immune activation. We sought to investigate the extent to which placental iron storage and macrophage accumulations were altered in GDM.Method of Study: We conducted a retrospective, case‐control study of archived placental tissues obtained from 22 pregnancies complicated by GDM and 22 unaffected controls. Controls were matched to cases based on maternal age, gestational age at birth, and method of delivery. Placental tissues were assessed for altered histology and CD68 and CD163 staining. Tissue iron was assessed using Prussian blue staining.Results: Maternal hematocrit levels were higher in GDM participants compared to controls (P = 0.02). The presence of meconium‐laden macrophages was significantly greater within the amnion of GDM cases (adjusted odds ratio (OR) 12.51). Although the total abundance of CD68‐expressing macrophages was not significantly different between groups, we detected a significantly greater abundance of CD163 expression within the chorion and decidua of cases. The total area staining positive for iron was 24% (95% confidence intervals of 2%‐46%) greater in GDM placentae versus controls.Conclusion: GDM is associated with altered placental histology and increases in meconium‐laden macrophages. Greater iron stores within the placentae of women with GDM is consistent with reports that iron excess is associated with an increased risk for GDM. The higher level of expression of CD163 on macrophage‐like cells of the chorion and decidua in GDM suggests an increase in M2‐like macrophages. Overall, our results add to growing evidence that GDM has direct effects on placental structure.
- 9 July 2018
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 80 (4) , e13020
Gestational diabetes mellitus is associated with increased CD163 expression and iron storage in the placenta
Problem: GDM has been associated with disturbances in iron homeostasis and exaggerated immune activation. We sought to investigate the extent to which placental iron storage and macrophage accumulations were altered in GDM.Method of Study: We conducted a retrospective, case‐control study of archived placental tissues obtained from 22 pregnancies complicated by GDM and 22 unaffected controls. Controls were matched to cases based on maternal age, gestational age at birth, and method of delivery. Placental tissues were assessed for altered histology and CD68 and CD163 staining. Tissue iron was assessed using Prussian blue staining.Results: Maternal hematocrit levels were higher in GDM participants compared to controls (P = 0.02). The presence of meconium‐laden macrophages was significantly greater within the amnion of GDM cases (adjusted odds ratio (OR) 12.51). Although the total abundance of CD68‐expressing macrophages was not significantly different between groups, we detected a significantly greater abundance of CD163 expression within the chorion and decidua of cases. The total area staining positive for iron was 24% (95% confidence intervals of 2%‐46%) greater in GDM placentae versus controls.Conclusion: GDM is associated with altered placental histology and increases in meconium‐laden macrophages. Greater iron stores within the placentae of women with GDM is consistent with reports that iron excess is associated with an increased risk for GDM. The higher level of expression of CD163 on macrophage‐like cells of the chorion and decidua in GDM suggests an increase in M2‐like macrophages. Overall, our results add to growing evidence that GDM has direct effects on placental structure.